Aptar Pharma and Aceso Therapeutics have formed a development collaboration around ACT-101, a preclinical inhaled antisense oligonucleotide intended to increase production of functional CFTR protein in people with cystic fibrosis. Aptar’s specialist inhalation business Nanopharm will lead formulation development and device assessment, addressing one of the central translational challenges facing RNA therapeutics for lung disease: getting a fragile nucleic-acid medicine through an inhalation device and into the relevant airway cells at a reproducible dose. ACT-101 remains preclinical and has not been tested in humans or approved by any regulator.
The mechanism is distinctive because Aceso is not attempting to replace or edit the defective CFTR gene. ACT-101 is designed to bind regulatory regions within the 3′ untranslated region of CFTR messenger RNA and mask sites where microRNAs can promote degradation of that message. By stabilizing the patient’s existing CFTR mRNA, Aceso hopes cells will make more CFTR protein from the gene copies they already carry. The company reports preclinical restoration of CFTR functional activity of up to 60% in patient-derived bronchial epithelial models spanning several clinically relevant genotypes, including F508del, I507del, N1303K and Y122X.
How is ACT-101 different from current CFTR modulator medicines?
Modern CF treatment has been transformed by small-molecule CFTR modulators that help defective CFTR protein fold, reach the cell surface or function more effectively. These medicines can produce major improvements for many patients carrying susceptible mutations, particularly the common F508del variant. Yet their effectiveness depends partly on the specific molecular defect and on the presence of enough CFTR protein for a modulator to act upon.
ACT-101 aims to intervene one step earlier. Instead of primarily improving the folding or gating of an existing protein, the antisense molecule is designed to stabilize CFTR messenger RNA so the cell produces more endogenous CFTR protein. In theory, increasing the amount of protein available could provide activity by itself and could also create more substrate for existing modulators to correct. Aceso reports preclinical evidence of both monotherapy activity and additional functional benefit when ACT-101 was combined with current CFTR modulator triple therapy.
This upstream strategy is one reason Aceso believes the platform may eventually reach mutation groups that respond incompletely to current drugs. That remains a hypothesis until clinical trials show how much RNA stabilization can actually occur inside human airway cells after inhaled dosing.
What does ACT-101 actually do to CFTR messenger RNA?
Messenger RNA is the temporary molecular instruction copied from DNA and used by cellular machinery to manufacture protein. Cells regulate how long each mRNA molecule survives, partly through microRNAs that bind specific sequences and can accelerate degradation or suppress translation.
Aceso’s Post-Transcriptional Gene Restoration platform is built around antisense oligonucleotides that occupy selected regulatory sites on an mRNA. ACT-101 is intended to mask microRNA-binding regions within the 3′ UTR of CFTR mRNA. If those regulatory microRNAs can no longer bind effectively, the message may survive longer, creating more opportunities for the cell to manufacture CFTR protein.
The approach does not alter genomic DNA, which differentiates it from CRISPR-style gene editing. It also does not introduce a new full-length CFTR gene in the manner of gene-replacement therapy. Instead, it attempts to make better use of the patient’s own endogenous transcript.
That could offer a different risk-benefit profile from permanent gene editing, but it also means treatment would probably need to be repeated because antisense oligonucleotides and their effects are not permanent.
What does the reported “up to 60% CFTR restoration” actually mean?
Aceso says preclinical studies used primary patient-derived bronchial epithelial cells grown at an air-liquid interface, a laboratory model designed to reproduce several features of human airway tissue. In those experiments, ACT-101 produced CFTR functional activity reaching as high as 60% across selected genotypes including F508del homozygous and compound heterozygous cells, I507del, N1303K and the Y122X nonsense mutation.
The figure is encouraging because relatively modest restoration of CFTR function can potentially have clinical importance in cystic fibrosis. However, “up to 60%” represents the strongest reported preclinical result rather than an average response that can be expected in patients.
Laboratory epithelial cultures allow researchers to deliver a carefully controlled dose directly to cells and measure ion-channel activity under optimized conditions. A human lung presents far more difficult barriers, including mucus, inflammation, uneven airway deposition, clearance mechanisms and variable disease severity.
The correct conclusion is therefore that ACT-101 has demonstrated meaningful proof of concept in established preclinical airway models. It has not demonstrated 60% CFTR restoration in a patient.
Why is Aptar Pharma involved if Aceso already has the RNA molecule?
For an inhaled medicine, formulation and delivery hardware are part of the therapeutic problem. An antisense sequence that performs exceptionally well when pipetted onto cultured cells may fail clinically if it is degraded during nebulization, deposited primarily in the throat, unable to penetrate airway mucus or delivered inconsistently between patients.
Nanopharm specializes in orally inhaled and nasal drug-product development and will evaluate formulation and device options for ACT-101. The collaboration is intended to support Aceso’s clinical-development roadmap rather than simply provide an off-the-shelf inhaler.
Developers need to know whether the oligonucleotide remains chemically intact through aerosol generation, what particle or droplet characteristics reach the desired lung regions, how much drug is lost inside the device and whether a practical administration time can deliver the intended dose.
These factors eventually become part of the regulatory package. A successful drug formulation cannot be separated from the device used to administer it if that device materially determines delivered dose.
Why is delivering RNA directly to the lung attractive for cystic fibrosis?
Systemically administered RNA medicines must circulate through the bloodstream and reach the desired organ in sufficient concentration. The lung offers the theoretical advantage of direct local administration through inhalation, potentially increasing exposure at the disease site while limiting unnecessary systemic distribution.
Cystic fibrosis also presents exactly the kind of chronic pulmonary disease in which local genetic or RNA therapy is compelling because the underlying CFTR defect is expressed in airway epithelial cells. Researchers have consequently pursued several inhaled modalities, including mRNA replacement, gene therapy and antisense approaches.
The lung is not easy to treat, however. Thick mucus is a defining feature of CF, and diseased airways can have altered ventilation patterns that make aerosol deposition uneven. Nucleic acids are vulnerable to enzymatic degradation and often require formulation technologies that help them remain stable and enter cells efficiently.
Aptar and Nanopharm’s involvement is therefore not a peripheral manufacturing detail. Drug delivery may determine whether ACT-101’s molecular mechanism is clinically usable at all.
Could ACT-101 work for patients whose mutations are poorly served by current modulators?
That is one of Aceso’s longer-term ambitions. Its broader pipeline includes programs intended to address several CFTR mutation classes, and ACT-101 has generated preclinical data in more than one genotype. Aceso specifically describes its platform as being built for patients with incomplete or absent responses to currently available treatments.
Nevertheless, mutation coverage needs clinical proof. A nonsense mutation that produces very little usable CFTR transcript presents a different biological problem from F508del, where protein is produced but processed incorrectly. Stabilizing mRNA may provide different degrees of benefit depending on how much transcript exists and what protein the mutation ultimately produces.
Aceso’s published pipeline currently emphasizes ACT-101 particularly around Class II disease, with other candidates planned for Class I and additional mutation categories. This suggests the company itself recognizes that one RNA-stabilization molecule may not be universally effective across every CFTR variant.
How close is ACT-101 to being tested in people?
It is not yet in a clinical trial. Aceso describes ACT-101 as being in preclinical and IND-enabling or clinical-readiness development, with a Clinical Trial Application target in 2027 and human clinical development planned thereafter. Its own materials describe beginning human studies as a target around 2028, assuming development and financing progress successfully.
Before first dosing, the company needs toxicology, biodistribution, pharmacology, manufacturing and inhalation-device data sufficient for regulators to permit clinical testing. Repeat-dose inhalation safety will be particularly important because the target tissue is the lung and treatment would likely be chronic.
The Aptar collaboration therefore represents a translational milestone rather than a clinical one. ACT-101 is moving from an academic and preclinical RNA concept toward a candidate that must be formulated, packaged and delivered in a way suitable for human testing.
What are the main safety questions for an inhaled antisense medicine?
One concern is unintended binding. Antisense oligonucleotides are designed to recognize specific RNA sequences, but developers need to understand whether the molecule has relevant off-target interactions that alter unrelated genes.
Local pulmonary inflammation is another important issue. Repeated exposure to an oligonucleotide or formulation excipients could potentially irritate airways, trigger innate immune signaling or exacerbate respiratory symptoms.
Systemic exposure also needs characterization even for an inhaled product. Some fraction of a lung-delivered medicine may cross into circulation or be swallowed, and regulators need to know where the molecule distributes and how it is eliminated.
Aceso says in-vivo biodistribution and repeat-dose studies have so far produced a favorable preclinical safety profile and target engagement, but these remain preclinical company-reported findings. Human safety cannot be inferred until controlled clinical trials begin.
Could ACT-101 eventually be used together with existing triple therapy?
This may be one of its most commercially plausible paths. For patients who derive substantial but incomplete benefit from current CFTR modulators, replacing an established effective therapy with a completely new RNA drug would require very strong evidence. Adding ACT-101 to existing treatment could be easier to justify if increased CFTR mRNA translates into additional functional protein that modulators can further rescue.
Aceso says preclinical experiments have shown additive functional benefit when ACT-101 was combined with existing CFTR modulator triple therapy.
Later trials would need to test whether this produces clinically meaningful improvement in lung function, sweat chloride, pulmonary exacerbations or quality of life rather than merely an incremental laboratory signal.
The drug could have a different role in patients with mutations poorly served by modulators, where monotherapy activity would matter more.
What should the cystic fibrosis field watch next?
The immediate milestones are formulation selection, inhalation-device development and completion of IND-enabling toxicology. Aceso’s 2027 CTA target provides a practical timeline against which progress can be judged.
The first human study would almost certainly focus initially on safety, pharmacokinetics and biological evidence that inhaled ACT-101 reaches airway cells and changes CFTR-related biomarkers. Demonstrating target engagement in the human lung would be the critical bridge between attractive epithelial-cell data and meaningful drug development.
ACT-101 is worth following because its mechanism occupies a middle ground between conventional small-molecule modulation and permanent genetic intervention. It does not rewrite DNA and does not replace the CFTR gene. It attempts to preserve the cell’s existing CFTR message long enough to produce more protein, then deliver that RNA medicine directly into the organ where it is needed.
Aptar’s role now is to determine whether that elegant molecular idea can survive contact with a real inhalation device and a diseased human lung. Until then, the reported 60% restoration remains an important preclinical result rather than evidence of benefit in people with cystic fibrosis.
